Terms: = Prostate cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1
1122 results:
1. Infection risk reduction with povidone-iodine rectal disinfection prior to transrectal prostate biopsy: an updated systematic review and meta-analysis.
Tsuboi I; Matsukawa A; Parizi MK; Klemm J; Mancon S; Chiujdea S; Fazekas T; Laukhtina E; Kawada T; Katayama S; Iwata T; Bekku K; Wada K; Araki M; Shariat SF
World J Urol; 2024 Apr; 42(1):252. PubMed ID: 38652324
[TBL] [Abstract] [Full Text] [Related]
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Laversanne M; Sung H; Ferlay J; Siegel RL; Soerjomataram I; Jemal A
CA Cancer J Clin; 2024; 74(3):229-263. PubMed ID: 38572751
[TBL] [Abstract] [Full Text] [Related]
3. Challenges in Diagnosis and Treatment of Male Hypogonadism.
Purnamasari D
Acta Med Indones; 2024 Jan; 56(1):1-2. PubMed ID: 38561883
[TBL] [Abstract] [Full Text] [Related]
4. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract] [Full Text] [Related]
5. Open-top Bessel beam two-photon light sheet microscopy for three-dimensional pathology.
Park WY; Yun J; Shin J; Oh BH; Yoon G; Hong SM; Kim KH
Elife; 2024 Mar; 12():. PubMed ID: 38488831
[TBL] [Abstract] [Full Text] [Related]
6. Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants.
Chen Y; Xie Y; Ci H; Cheng Z; Kuang Y; Li S; Wang G; Qi Y; Tang J; Liu D; Li W; Yang Y
BMC Med; 2024 Mar; 22(1):90. PubMed ID: 38433226
[TBL] [Abstract] [Full Text] [Related]
7. Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis.
Mohamad O; Nicosia L; Mathier E; Riggenbach E; Zamboglou C; Aebersold DM; Alongi F; Shelan M
Brachytherapy; 2024; 23(3):309-320. PubMed ID: 38431441
[TBL] [Abstract] [Full Text] [Related]
8. Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer.
Plym A; Madueke I; Naik S; Isabelle M; Conti DV; Haiman CA; Penney KL; Mucci LA; Khorasani R; Kibel AS
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38429995
[TBL] [Abstract] [Full Text] [Related]
9. Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy - An evaluation of dosimetric performances.
Böhlen TT; Germond JF; Desorgher L; Veres I; Bratel A; Landström E; Engwall E; Herrera FG; Ozsahin EM; Bourhis J; Bochud F; Moeckli R
Radiother Oncol; 2024 May; 194():110177. PubMed ID: 38378075
[TBL] [Abstract] [Full Text] [Related]
10. prostate cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract] [Full Text] [Related]
11. The effect of limited english proficiency on prostate-specific antigen screening in American men.
Stone BV; Labban M; Beatrici E; Filipas DK; Frego N; Qian ZJ; Voleti SS; Osman NY; Pomerantz MM; Lipsitz SR; Feldman AS; Kibel AS; Cole AP; Trinh QD
World J Urol; 2024 Jan; 42(1):54. PubMed ID: 38244128
[TBL] [Abstract] [Full Text] [Related]
12. Enhancing Metabolome Annotation by Electron Impact Excitation of Ions from Organics-Molecular Networking.
Wang X; Sun X; Wang F; Wei C; Zheng F; Zhang X; Zhao X; Zhao C; Lu X; Xu G
Anal Chem; 2024 Jan; 96(4):1444-1453. PubMed ID: 38240194
[TBL] [Abstract] [Full Text] [Related]
13. Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.
Sanguineti G; Pavarini M; Munoz F; Magli A; Cante D; Garibaldi E; Gebbia A; Noris Chiorda B; Girelli G; Villa E; Faiella A; Magdalena Waskiewicz J; Avuzzi B; Pastorino A; Moretti E; Rago L; Statuto T; Gatti M; Rancati T; Valdagni R; Luigi Vavassori V; Gisella Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2024 Mar; 192():110088. PubMed ID: 38199284
[TBL] [Abstract] [Full Text] [Related]
14. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
15. Risk of Biochemical Recurrence in Patients With Grade Group 1 prostate cancer With Extraprostatic Extension Treated With Radical prostatectomy.
Rezaee ME; Pallauf M; Fletcher SA; Han M; Pavlovich CP; Cornelia Ding CK; Epstein JI; Allaf ME; Trock BJ; Singla N
J Urol; 2024 Mar; 211(3):407-414. PubMed ID: 38109699
[TBL] [Abstract] [Full Text] [Related]
16. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
17. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
[TBL] [Abstract] [Full Text] [Related]
18. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Shen J; Chowdhury S; Agarwal N; Karsh LI; Oudard S; Gartrell BA; Feyerabend S; Saad F; Pieczonka CM; Chi KN; Brookman-May SD; Rooney B; Bhaumik A; McCarthy SA; Bevans KB; Mundle SD; Small EJ; Smith MR; Graff JN
Br J Cancer; 2024 Jan; 130(1):73-81. PubMed ID: 37951974
[TBL] [Abstract] [Full Text] [Related]
19. prostate cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for prostate cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract] [Full Text] [Related]
20. A tumour-spheroid manufacturing and cryopreservation process that yields a highly reproducible product ready for direct use in drug screening assays.
Shajib MS; Futrega K; Davies AM; Franco RAG; McKenna E; Guillesser B; Klein TJ; Crawford RW; Doran MR
J R Soc Interface; 2023 Oct; 20(207):20230468. PubMed ID: 37817581
[TBL] [Abstract] [Full Text] [Related]
[Next]
